HRP20110148T1 - Koncentrirane otopine metotreksata - Google Patents

Koncentrirane otopine metotreksata Download PDF

Info

Publication number
HRP20110148T1
HRP20110148T1 HR20110148T HRP20110148T HRP20110148T1 HR P20110148 T1 HRP20110148 T1 HR P20110148T1 HR 20110148 T HR20110148 T HR 20110148T HR P20110148 T HRP20110148 T HR P20110148T HR P20110148 T1 HRP20110148 T1 HR P20110148T1
Authority
HR
Croatia
Prior art keywords
methotrexate
accordance
intended
use according
disease
Prior art date
Application number
HR20110148T
Other languages
English (en)
Croatian (hr)
Inventor
Will Heiner
Original Assignee
Medac Gesellschaft f�r klinische Spezialpr�parate mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38640096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110148(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medac Gesellschaft f�r klinische Spezialpr�parate mbH filed Critical Medac Gesellschaft f�r klinische Spezialpr�parate mbH
Publication of HRP20110148T1 publication Critical patent/HRP20110148T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
HR20110148T 2006-07-21 2011-02-28 Koncentrirane otopine metotreksata HRP20110148T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006033837A DE102006033837A1 (de) 2006-07-21 2006-07-21 Konzentrierte Methotrexat-Lösungen
PCT/EP2007/006491 WO2008009476A2 (fr) 2006-07-21 2007-07-20 Solutions de méthotrexate concentrées

Publications (1)

Publication Number Publication Date
HRP20110148T1 true HRP20110148T1 (hr) 2011-03-31

Family

ID=38640096

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110148T HRP20110148T1 (hr) 2006-07-21 2011-02-28 Koncentrirane otopine metotreksata

Country Status (22)

Country Link
US (7) US8664231B2 (fr)
EP (2) EP2046332B1 (fr)
JP (1) JP5683810B2 (fr)
KR (1) KR101260554B1 (fr)
AT (2) AT14872U1 (fr)
AU (1) AU2007276387B2 (fr)
BR (1) BRPI0715433A2 (fr)
CA (2) CA2659662C (fr)
CY (1) CY1111159T1 (fr)
DE (3) DE102006033837A1 (fr)
DK (1) DK2046332T3 (fr)
ES (1) ES2355399T3 (fr)
HR (1) HRP20110148T1 (fr)
ME (1) ME01940B (fr)
MX (1) MX2009000812A (fr)
PL (1) PL2046332T3 (fr)
PT (1) PT2046332E (fr)
RS (1) RS51688B (fr)
RU (1) RU2403044C1 (fr)
SI (1) SI2046332T1 (fr)
UA (1) UA95488C2 (fr)
WO (1) WO2008009476A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209095A1 (en) 2002-02-11 2003-09-04 Antares Pharma, Inc. Intradermal injector
DK1850892T4 (da) 2005-01-24 2023-06-06 Antares Pharma Inc Forfyldt nål-assisteret sprøjtejetinjektor
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
CA2670288C (fr) * 2006-11-21 2015-10-27 Kalobios Pharmaceuticals, Inc. Procedes de traitement des maladies inflammatoires chroniques a l'aide d'un antagoniste du gm-csf
EP2990067B1 (fr) 2008-03-10 2019-09-04 Antares Pharma, Inc. Dispositif de sécurité d'injecteur
EP2318075B1 (fr) 2008-08-05 2019-05-22 Antares Pharma, Inc. Injecteur à dosage multiple
WO2010108116A1 (fr) * 2009-03-20 2010-09-23 Antares Pharma, Inc. Système d'injection d'agents dangereux
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
DK2822618T3 (da) 2012-03-06 2024-01-22 Antares Pharma Inc Forfyldt nål med brudkraftfunktion
AU2013203784A1 (en) * 2012-04-06 2013-10-24 Kaushik J. Dave Needle assisted jet injection administration of testosterone compositions
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
EP4297200A3 (fr) * 2013-01-29 2024-03-27 Sanofi-Aventis Deutschland GmbH Module électronique et dispositif d'administration de médicament
JP2016507305A (ja) 2013-02-11 2016-03-10 アンタレス・ファーマ・インコーポレーテッド トリガ力を低減した針支援式ジェット注射装置
EP2968792B1 (fr) 2013-03-11 2019-05-15 Antares Pharma, Inc. Injecteur de dose avec système à pignon
WO2014165136A1 (fr) * 2013-03-12 2014-10-09 Antares Pharma, Inc. Seringues pré-remplies à volume constant et leurs trousses
WO2015147018A1 (fr) * 2014-03-28 2015-10-01 テルモ株式会社 Formulation aqueuse injectable pour traiter des maladies auto-immunes inflammatoires
WO2015161015A1 (fr) * 2014-04-16 2015-10-22 Antares Pharma, Inc. Procédé permettant d'obtenir une disponibilité systémique accrue de méthotrexate
WO2015183213A1 (fr) 2014-05-28 2015-12-03 Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique
JP2017066073A (ja) * 2015-09-29 2017-04-06 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤およびその保存方法
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
GB2591681A (en) * 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357971A (en) * 1980-09-19 1982-11-09 Cyberon Corporation Syringe gauging, loading and injection apparatus
US5279586A (en) * 1992-02-04 1994-01-18 Becton, Dickinson And Company Reusable medication delivery pen
US5681291A (en) * 1992-11-19 1997-10-28 Tebro S.A. Disposable auto-injector for prefilled syringes
US5593671A (en) 1994-07-01 1997-01-14 American Cyanamid Company Method of attenuating lung capillary leak in a mammal
US5542934A (en) * 1995-06-02 1996-08-06 Silver; Richard M. Multiple carpule hypodermic syringe
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
WO2002070007A1 (fr) * 2001-03-02 2002-09-12 Medimmune, Inc. Prevention ou traitement de troubles inflammatoires ou auto-immuns par l'administration d'antagonistes de l'integrine $g(a)v$g(b)¿3?
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US20050153969A1 (en) * 2004-01-13 2005-07-14 Iomed, Inc. Methods for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicament
DE102006033837A1 (de) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen

Also Published As

Publication number Publication date
RU2009106053A (ru) 2010-08-27
KR20090079876A (ko) 2009-07-22
EP2046332B1 (fr) 2010-12-15
US11944629B2 (en) 2024-04-02
WO2008009476A2 (fr) 2008-01-24
CA2659662A1 (fr) 2008-01-24
EP2046332A2 (fr) 2009-04-15
US10610531B2 (en) 2020-04-07
US20200246342A1 (en) 2020-08-06
AT14872U1 (de) 2016-08-15
SI2046332T1 (sl) 2011-02-28
WO2008009476A3 (fr) 2008-11-06
US20140155405A1 (en) 2014-06-05
AU2007276387A2 (en) 2009-04-02
RU2403044C1 (ru) 2010-11-10
US20100016326A1 (en) 2010-01-21
CY1111159T1 (el) 2015-06-11
DE202007019703U1 (de) 2015-10-28
PL2046332T3 (pl) 2011-05-31
ATE491455T1 (de) 2011-01-15
BRPI0715433A2 (pt) 2013-07-23
RS51688B (en) 2011-10-31
DE502007005972D1 (de) 2011-01-27
US8664231B2 (en) 2014-03-04
AU2007276387A1 (en) 2008-01-24
CA2869671A1 (fr) 2008-01-24
DK2046332T3 (da) 2011-03-07
ME01940B (fr) 2011-10-31
MX2009000812A (es) 2009-07-10
US20190038629A1 (en) 2019-02-07
UA95488C2 (ru) 2011-08-10
EP2292235A3 (fr) 2011-06-01
US20170246172A1 (en) 2017-08-31
JP5683810B2 (ja) 2015-03-11
DE102006033837A1 (de) 2008-01-31
US20150164902A1 (en) 2015-06-18
KR101260554B1 (ko) 2013-05-06
EP2292235A2 (fr) 2011-03-09
CA2659662C (fr) 2015-01-20
US20140179703A1 (en) 2014-06-26
ES2355399T3 (es) 2011-03-25
JP2009544636A (ja) 2009-12-17
AU2007276387B2 (en) 2010-09-30
PT2046332E (pt) 2011-02-04

Similar Documents

Publication Publication Date Title
HRP20110148T1 (hr) Koncentrirane otopine metotreksata
HRP20171939T1 (hr) Formulacija protutijela i režimi terapije
HRP20191923T1 (hr) Postupci i sastavi za isporuku arilsulfataze a u cns
HRP20191994T1 (hr) Formulacije ketorolaka spremne za uporabu
JP2017031213A5 (fr)
HRP20170270T1 (hr) Metoda davanja plućnog surfaktanta
JP2010511596A5 (fr)
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
RU2016139373A (ru) Растворы бупренорфина с замедленным высвобождением
RU2010129824A (ru) Новый функционально активный, высокоочищенный, стабильный конъюгат интерферона альфа с полиэтиленгликолем, представленный одним позиционным изомером пэг-nаh-ифн, с уменьшенной иммуногенностью, с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
WO2007022609B1 (fr) Composition pharmaceutique de morphine sous forme de solution injectable prete a l'emploi et forme posologique unitaire de morphine pour administration epidurale ou intrathecale
CN102266549A (zh) 一种含有阿加曲班的注射用制剂
CA2496121A1 (fr) Formulations stables d'acide hyaluronique pour le traitement therapeutique des arthropathies
RU2021118782A (ru) Способ лечения сосудистых заболеваний
JP4707327B2 (ja) ポリペプタイド類の吸着防止剤
Kwon et al. Drug Conversion from a Mixture of Fentanyl and Bupivacaine to Morphine in Intrathecal Drug Administration Pump: A Case Report
KR20140050593A (ko) 히알루론산 또는 히알루론산염을 포함하는 수용액
KR20140024863A (ko) 히알루론산 또는 히알루론산염을 포함하는 수용액
RU2023130545A (ru) Фармацевтические композиции, содержащие пикрозид
CN105061565A (zh) 干扰素调节因子5抑制多肽及其应用
UA55302U (uk) Стабільна фармацевтична композиція на основі інтерферону-альфа 2b
PL1683518T3 (pl) Preparat farmaceutyczny zawierający formoterol i glikol propylenowy